Ascendis Pharma A/S

From Verify.Wiki
Jump to: navigation, search
Ascph.jpg
www.ascendispharma.com
Ascendis Pharma A/S
Type Public
Industry BioTechnology
Founded 2007
Headquarters Capital Region of Denmark, Denmark
Key people 55 [1]
Investors Gilde Healthcare Partners, OrbiMed, RA Capital Management, Rock Springs Capital, Sofinnova Partners, Sofinnova Ventures, TechnoStart, Venrock, Vivo Capital [2]
Number of employees Jan Møller Mikkelsen (Co-Founder, President and CEO), Martin Auster (CBO), Michael Beckert (Chief Medical Officer (acting)), Thomas Soloway (CFO)

Ascendis Pharma A/S is an emerging pharmaceutical company which is creating improved, patentable versions of both currently marketed drugs and high-value development-stage opportunities. The company is built upon a novel transient linker technology, TransientLink, which conjugates peptides, proteins and small molecules to a carrier molecule in a reversible fashion. This unique reversibility allows an unmodified active drug to be released (unlinked) in the body in a precise, time-controlled fashion, creating a long-acting effect. Conventional conjugation technologies are unable to achieve this type of slow-release mechanism because the polymer cannot de-link from the drug. [3]

Products

Ascendis Pharma A/S, a clinical stage biopharmaceutical company

  • It develops various prodrug therapies to treat unmet medical needs.
  • It is developing TransCon human growth hormone that has completed Phase II clinical trials in children and adults to treat growth hormone deficiency (GHD) and other indications
  • TransCon Treprostinil that has completed Phase I clinical trial for the treatment of pulmonary arterial hypertension, a life-threatening disease characterized by elevated blood pressure in the pulmonary arteries.
  • The company is also developing TransCon Peptides for the treatment of diabetes
  • TransCon Ranibizumab, a compound to support injection of ranibizumab.
  • It has strategic collaborations with Sanofi and Genentech

[4]

Controversies

None Reported

Top 5 Recent Tweets

DateAuthorComment
September 26, 2020OrbiMedAscendis Pharma A/S Announces U.S. Food and Drug Administration (FDA) Accepts Biologics License Application (BLA) f… https://t.co/gafMCq6Cvl
September 26, 2020OrbiMedAscendis Pharma A/S Submits Marketing Authorisation Application (MAA) to the European Medicines Agency (EMA) for Tr… https://t.co/wR27i5C6nz
September 25, 2020OrbiMedAscendis Pharma A/S Announces Filing of the Clinical Trial Notification for Phase 3 Clinical Trial of TransCon™ hGH… https://t.co/n7PDhA2qNH
September 25, 2020abutsincAscendis Pharma A/S Announces Filing of the Clinical Trial Notification for Phase 3 Clinical Trial of TransCon™ hGH… https://t.co/ZeS2yUvc0F


Top 5 Recent News Headlines

Top 5 Lifetime Tweets

Top 5 Lifetime News Headlines

  1. http://www.nasdaq.com/markets/ipos/company/ascendis-pharma-as-951656-77256
  2. https://www.crunchbase.com/organization/ascendis-pharma#/entity
  3. http://www.bionity.com/en/companies/14852/ascendis-pharma-a-s.html
  4. http://www.bloomberg.com/research/stocks/private/snapshot.asp?privcapid=39510693

Verification history